Tumor-targeting glycol chitosan nanocarriers: overcoming the challenges posed by chemotherapeutics

Yongwhan Choi, Seungho Lim, Hong Yeol Yoon, Byung Soo Kim, Ick Chan Kwon, Kwangmeyung Kim

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


Introduction: In the past decade, the glycol chitosan nanocarriers (GCNCs) have been widely used for tumor-targeted delivery of anticancer agents such as chemo drugs, peptides, and genes due to their biocompatibility, biodegradability, and easy fabrication. In particular, GCNCs can effectively solubilize water-insoluble chemo drugs as well as improve the delivery efficiency of chemo drugs to the tumor, resulting in maximizing therapeutic efficacy and minimizing side effect. In this review, we introduce the various applications of GCNCs for cancer treatment and these GCNCs demonstrate the great potential in overcoming challenges of chemotherapeutics. Areas covered: Various designs of GC nanocarriers have been reviewed. The current state of GC nanocarriers for delivering chemotherapeutics with a focus on their physicochemical properties including solubilization of anti-cancer drugs, sustained release, and tumor-selectivity. Furthermore, state of the art in delivery and therapeutic strategy using GC nanocarriers also introduced for overcoming challenges of chemotherapeutics. Expert opinion: Based on the reviewed literature, physicochemical properties of GC nanocarriers will have a great potential to overcome challenges posed by chemotherapeutics.

Original languageEnglish
Pages (from-to)835-846
Number of pages12
JournalExpert Opinion on Drug Delivery
Issue number8
Publication statusPublished - 2019

Bibliographical note

Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.


  • Glycol chitosan nanocarrier
  • cancer therapy
  • chemotherapy
  • drug delivery

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Tumor-targeting glycol chitosan nanocarriers: overcoming the challenges posed by chemotherapeutics'. Together they form a unique fingerprint.

Cite this